GlassScriptPhysician profile
Gerard Casale
NPI 1831199165
$5,729.87
in general payments reported to CMS, 2019-2025
15 companies · $540 in 2025
The $540 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,439 · 2020: $264 · 2021: $373 · 2022: $177 · 2023: $1,269 · 2024: $1,667 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,475.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,994.02 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $1,487.70 | 2019-2024 | Arexvy, Bexsero |
| Phathom Pharmaceuticals, INC. | $479.28 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $400.61 | 2023-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $345.48 | 2019 | |
| Amgen INC. | $234.11 | 2019 | |
| Novo Nordisk INC | $215.52 | 2019 | |
| Merck Sharp & Dohme LLC | $155.37 | 2019-2025 | Capvaxive, Gardasil 9 |
| Pfizer INC. | $152.65 | 2019-2024 | |
| Allergan, INC. | $125.00 | 2019 | |
| Exact Sciences Corporation | $43.68 | 2024-2025 | Cologuard Collection Kit |
| Vbi Vaccine (Delaware) INC. | $37.64 | 2022 | |
| Organon LLC | $24.26 | 2022 | |
| Gilead Sciences, INC. | $19.80 | 2020 | |
| Lilly USA, LLC | $14.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerard Casale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.